HemOnc Today New York

The latest news from the annual meeting, including video perspective from faculty members and attendees.


Meeting NewsVideo

VIDEO: Joint blockade of PD-1, CTLA-4 is ‘viable option’ in melanoma

March 29, 2019
NEW YORK — Steven J. O’Day, MD, executive director of John Wayne Cancer Institute, spoke at HemOnc Today New York about efforts to find…
Meeting NewsVideo

VIDEO: HemOnc Today New York’s ‘understandable, meaningful format’ simplifies complicated topics

March 28, 2019
This year’s HemOnc Today New York meeting provided expert perspectives on advances in cancer treatment and practical insights to help members…
Meeting NewsVideo

VIDEO: Continuing immunotherapy after NSCLC progression is ‘individualized treatment decision’

March 26, 2019
NEW YORK — Benjamin P. Levy, MD, associate professor at Johns Hopkins School of Medicine and clinical director of Johns Hopkins Sidney Kimmel…
Meeting News

Toxicity, costs must be considered when using chemotherapy-immunotherapy combinations for lung cancer

March 25, 2019
Two faculty members at HemOnc Today New York debated whether immunotherapy alone or in combination with chemotherapy is the ideal treatment approach…
Meeting News

Experts debate CAR T-cell therapy vs. transplant for relapsed diffuse large B-cell lymphoma

March 23, 2019
NEW YORK — Chimeric antigen receptor T-cell therapy confers better outcomes than autologous stem cell transplant to some patients with relapsed…

CAR T-cell therapy changing the landscape of lymphoma treatment

March 23, 2019
NEW YORK — Chimeric antigen receptor T cell therapies could be the breakthrough hematologists have sought to effectively treat certain patients…
Meeting News

Future ‘very bright’ in acute myeloid leukemia

March 23, 2019
NEW YORK — Treatment options for acute myeloid leukemia have evolved rapidly, but the expanded armamentarium has created a new set of…
Meeting News

First-line treatment for metastatic renal cell carcinoma evolving, but biomarkers still lacking

March 22, 2019
NEW YORK — First-line treatment of patients with metastatic renal cell carcinoma has evolved considerably in the past 18 months with FDA…
Meeting News

Rising PSA contributes to lack of clarity in nonmetastatic prostate cancer

March 22, 2019
NEW YORK — PSA is an “imperfect biomarker” that should inform prostate cancer treatment but not dictate it, according to a…

Molecular therapy for lung cancer has not evolved quickly enough

March 22, 2019
Molecular therapy for the treatment of lung cancer has not evolved enough to adequately extend survival of patients, according to a presenter at…